无载体放射性碘标记MIBG的制备及初步生物分布  

Preparation and Preliminary Biodistribution of No-Carrier-Added Meta[*I]iodobenzylguanidine

作　　者：樊彩云[1] 邓新荣[1] 刘子华[1] 李凤林[1] 罗志福[1] 

机构地区：[1]中国原子能科学研究院,北京102413

出　　处：《同位素》2015年第3期148-154,共7页Journal of Isotopes

摘　　要：无载体放射性碘标记间碘苄胍(no-carrier-added,n.c.a.123/131I-MIBG)在肿瘤、心肌显像和神经内分泌肿瘤的治疗方面有理论上优势。首先合成了以多氟化合物为支持体的标记前体,对该前体进行了放射性碘标记、纯化和初步生物分布实验。结果显示,无载体放射性碘125I标记MIBG在正常小鼠的心、脾、肺和肾上腺中的摄取显著高于目前商用的放射性碘标记MIBG。利用该方法标记后产物不需要使用HPLC进行纯化,适用于大规模临床应用。No-carrier-added meta-[＊I]iodobenzylguanidine（（n. c. a. ）[^123/131I]MIBG） has been considered to be promising diagnostic agents for oncology and cardiology, or as targeted radiotherapeutics for neuroendocrine tumors. The synthesis of a fluorous supported precursor for the purification without HPLC of n. c. a. [＊I]MIBG was presented and its structure was determined. The precursor was labeled with radioactive iodine and the preliminary biodistribution of n. e. a. [＊I]MIBG was studied. The uptake of n. c. a.[^125I] MIBG were significantly higher than that of c. a.[^125I]MIBG in heart, spleen, lung and adrenals. This facile preparation method of n. c. a.[＊I] MIBG would allow its wider application in clinic.

关 键 词：间碘苄胍 无载体 多氟化合物支持体 

分 类 号：TL923[核科学技术—核燃料循环与材料]